Meeting
2020 ASCO Virtual Scientific Program
Genome-wide association study of steady-state letrozole concentration in patients with breast cancer.
Authors
Daniel Louis Hertz
University of Michigan College of Pharmacy, Ann Arbor, MI
Daniel Louis Hertz , Julie Douglas , Kelley M. Kidwell , Christina L Gersch , Zeruesenay Desta , Anna Maria Storniolo , Vered Stearns , Todd C. Skaar , Daniel F. Hayes , Norah Lynn Henry , James M. Rae
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 538)
DOI
10.1200/JCO.2020.38.15_suppl.538
Abstract #
538
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone
Poster
2016 Cancer Survivorship Symposium
Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial.
First Author: Kunal C. Kadakia
Poster
2015 ASCO Annual Meeting
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).
First Author: Maysa M. Abu-Khalaf